Vertex Pharmaceuticals/VRTX

$393.48

0.09%
-
1D1W1MYTD1YMAX

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Ticker

VRTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Leiden

Employees

5,400

Headquarters

Boston, United States

VRTX Metrics

BasicAdvanced
$102.7B
Market cap
28.60
P/E ratio
$13.89
EPS
0.38
Beta
-
Dividend rate
$102.7B
0.38232
$448.40
$316.43
1.27M
3.987
3.779
2.139
2.139
25.931
17.71%
22.99%
20.93%
28.603
10.406
5.825
6.561
31.322
10.51%
8.37%
16.73%
10.51%

What the Analysts think about VRTX

Analyst Ratings

Majority rating from 32 analysts.
Buy

Price Targets

Average projection from 25 analysts.
18.47% upside
High $574.00
Low $325.00
$393.48
Current price
$466.14
Average price target

VRTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
38.47% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.52B
1.38%
Net income
$968.8M
-6.42%
Profit margin
38.47%
-7.7%

VRTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.37%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$3.05
$3.89
$4.08
$4.20
-
Expected
$3.00
$3.88
$3.97
$4.10
$4.04
Surprise
1.78%
0.21%
2.67%
2.37%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Vertex Pharmaceuticals stock?

Vertex Pharmaceuticals (VRTX) has a market cap of $102.7B as of April 19, 2024.

What is the P/E ratio for Vertex Pharmaceuticals stock?

The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 28.6 as of April 19, 2024.

Does Vertex Pharmaceuticals stock pay dividends?

No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Vertex Pharmaceuticals dividend payment date?

Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Vertex Pharmaceuticals?

Vertex Pharmaceuticals (VRTX) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Vertex Pharmaceuticals stock price target?

The target price for Vertex Pharmaceuticals (VRTX) stock is $466.14, which is 18.47% above the current price of $393.48. This is an average based on projections from 25 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vertex Pharmaceuticals stock

Buy or sell Vertex Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing